In August, a family reached out to Envita Medical Centers with questions about the care their father received at the clinic, which specializes in alternative cancer treatments. Envita responded through a spokesman and issued a legal warning against potential defamation claims. The clinic emphasized that it does not guarantee treatment outcomes and noted that patients, including the father in question, sign consent forms detailing their proposed treatments, associated risks, and expected costs.
Envita disputes the criticisms raised in a 2015 Food and Drug Administration (FDA) report, labeling them as unsubstantial. The clinic also clarified that Dr. Prato, referenced in the report, “does not practice clinically” and that a physician whose license was temporarily suspended is no longer employed by Envita. Regarding a previous case involving patient paralysis, the center stated that the matter was resolved without any admission of wrongdoing and does not reflect the clinic’s overall experience. Another physician associated with Envita was placed on probation by the Arizona Medical Board last year but remains with the organization. Envita highlighted that challenges are inevitable for any healthcare entity operating for more than two decades and affirmed its commitment to comply with FDA and other regulatory requirements.
The family’s investigation into Envita’s practices uncovered a broader landscape of similar clinics nationwide offering costly, unproven cancer therapies. Regulatory oversight for these clinics varies significantly across states, leading to a complex and inconsistent legal framework. Many such clinics have connections to practitioners with documented disciplinary histories, including allegations ranging from improper diagnoses to surgical errors and patient fatalities.
Alternative cancer treatments like those promoted by Envita are often not covered by insurance, imposing substantial financial burdens on patients and their families. Some fundraise through crowdfunding platforms or face severe financial hardship after liquidating assets to afford care. While the family of the patient discussed was able to manage these expenses, others have reported feelings of betrayal or misinformation and have resorted to leaving negative online reviews.
Medical experts consulted by the family expressed deep concern after reviewing the patient’s treatment records from Envita. Several oncologists found little to no scientific basis for the therapies prescribed; one described the plan as lacking any biologically plausible rationale, while another responded with shock.
The patient’s prognosis was poor from the outset. According to the oncologist who treated him at Memorial Sloan Kettering, Dr. Mark G. Kris, traditional chemotherapy might have improved quality of life but offered limited chances for long-term survival. He emphasized that while he could not promise extended life, patients have the right to choose treatments that provide them hope, cautioning that false hope can be harmful.
As the patient’s condition rapidly worsened in an intensive care unit in Scottsdale, Arizona, the family struggled to bring him home for his final days but was unable due to his fragile state. After extensive hospitalization, they decided to withdraw life support. In his final hours, the patient clung to the belief in a cure, requesting a medication—fenbendazole, a dog deworming drug reported anecdotally online as a cancer remedy—which his family reluctantly administered. The patient passed away the following day, highlighting the tragic consequences of pursuing unproven treatments in the face of terminal illness.
The family’s experience underscores the challenges faced by patients and families navigating complex choices about cancer treatment, often amid uncertain regulatory environments and conflicting medical information. Their story raises broader questions about the ethics and oversight of alternative cancer clinics in the United States.